secwatch.observer — SEC 8-K summary
======================================

Issuer:     Coya Therapeutics, Inc. (COYA)
CIK:        0001835022
Form:       8-K
Filed at:   2025-03-18T23:59:59+00:00
Accession:  0000950170-25-040779
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Coya Therapeutics FY2024 net loss $14.9M; cash $38.3M; pipeline updates for ALS and FTD trials
--------------------------------------------------------------------------------

- Net loss $14.9M in 2024 vs $8.0M in 2023; R&D expenses $11.9M (up from $5.5M).
- Cash and equivalents $38.3M as of Dec 31, 2024; raised $10M private placement and $5M from ADDF.
- Received $3.85M from Dr. Reddy's for COYA-302 ALS Phase 2; eligible for additional $8.4M milestone.
- Plan to submit nonclinical data to FDA in Q2 2025 for COYA-302 ALS Phase 2b trial initiation.
- Expect to file IND for COYA-302 Phase 2b in FTD in 2H 2025; top-line data from investigator trial also in 2H 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1835022/000095017025040779/0000950170-25-040779-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1835022/000095017025040779/coya-20250318.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-040779

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer